医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Oxea Announces Price Increase for Carboxylic Acids

2013年01月05日 AM12:25
このエントリーをはてなブックマークに追加


 

DALLAS

Oxea will increase list and off-list prices on the product below effective January 15, 2013, or as contracts allow.

Product   North America   Asia, Middle East
    USD/lb USD/mt
2-Ethylhexanoic acid 0,03 100

Oxea is a global manufacturer of oxo intermediates and oxo derivatives, such as alcohols, polyols, carboxylic acids, specialty esters, and amines. These products are used for the production of high-quality coatings, lubricants, cosmetics and pharmaceutical products, flavorings and fragrances, printing inks and plastics. In 2011, Oxea generated revenue of about EUR 1.5 billion with its 1,365 employees in Europe, the Americas and Asia.

For more information, visit www.oxea-chemicals.com.

CONTACT

Commercial contact:
OXEA Corporation, 1505 West LBJ Freeway,
Dallas, TX, 75234, USA
Cristóbal Ascencio, Vice President
Oxo-Derivatives
Phone +1 972-481-2700, fax +1 972-481-6023
info@oxea-chemicals.com,
www.oxea-chemicals.com
or
Press
contact:

OXEA GmbH, Otto-Roelen-Strasse 3, D-46147 Oberhausen
Birgit
Reichel, phone +49 (0) 208-693-3112, fax +49 (0) 208-693-3101
birgit.reichel@oxea-chemicals.com,
www.oxea-chemicals.com

同じカテゴリーの記事 

  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
  • ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology